The U.S. Food and Drug Administration (FDA) has given priority review to the antipsychotic med Abilify for the treatment of pediatric schizophrenia. The FDA made this move after Abilify was found effective in treating pediatric schizophrenia patients (ages 13 years to 17 years) in recent international studies. Priority review status is granted when the FDA intends to make a decision on the supplemental use of the med within six months.
Read moreRecently, the medication Abilify (aripiprazole) was approved by the FDA for the treatment of schizophrenia in the adolescent population... Read more »
A study at the Penn State College of Medicine says that "[r]educing the non-FDA-approved use of antipsychotic drugs may be a way to save... Read more »
Hi guys! It has been awhile since we have done a medication review. One of our members spoke about taking Abilify and so I thought... Read more »
Officials with the U.S. Food and Drug Administration (FDA) say they are reviewing dozens of products for potential safety problems. Among the... Read more »
The U.S. Food and Drug Administration has given expanded approval for the use of Abilify in treating bipolar disorder. The drug can now be used as a... Read more »
The U.S. Food and Drug Administration has approved Abilify to treat bipolar I disorder in children. The drug can now be used to ease manic and mixed... Read more »
The U.S. Food and Drug Administration (FDA) has granted priority review status to an application for the use of Abilify in children who suffer from... Read more »
Source: First DataBank
Generic Name: ARIPIPRAZOLE - INJECTION Pronounced: (ay-ree-PIP-ray-zole) Warning There may be a slightly increased risk of serious, possibly fatal... Read more »